TY - JOUR T1 - Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC A1 - Cantini, Luca A1 - Pecci, Federica A1 - Merloni, Filippo A1 - Lanese, Andrea A1 - Lenci, Edoardo A1 - Paoloni, Francesco A1 - Aerts, Joachim G J V A1 - Berardi, Rossana A1 - Oncology, Clinical A1 - Politecnica, Università A1 - Riuniti, A O U Ospedali Y1 - 2021/// KW - Immune checkpoint inhibitors KW - small cell lung cancer KW - mesothelioma KW - thymic epithelial tumor KW - immuno-oncology KW - immune modulating JF - Exploration of Targeted Anti-tumor Therapy VL - 2 SP - 1 EP - 25 DO - 10.37349/etat.2021.00030 UR - https://www.explorationpub.com/Journals/etat/Article/100230 L1 - file:///D:/未完成工作/上线/ARICHIVE-etat/100230-pub.pdf N2 - The introduction of immune checkpoint inhibitors (ICIs) in non-oncogene addicted non-small cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful improvement in patient prognosis. Disappointingly, the success of ICI therapy in NSCLC has not been fully replicated in other thoracic malignancies as small cell lung cancer (SCLC), malignant pleural mesothelioma (MPM), and thymic epithelial tumors (TETs), due to the peculiar biological features of these disease and to the difficulties in the conduction of well-designed, biomarker-driven clinical trials. Therefore, combination strategies of ICIs plus conventional therapies (either chemotherapy, alternative ICIs or targeted agents) have been implemented. Although first approvals of ICI therapy have been recently granted in SCLC and MPM (in combination with chemotherapy and different ICIs), results remain somewhat modest and limited to a small proportion of patients. This work reviews the trial results of ICI therapy in mesothelioma, SCLC, and TETs and discusses the potential of combining ICIs with old drugs. ER -